Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
- Conditions
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT00454636
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Professor David Cunningham
- Target Recruit Count
- 1103
- Registration Number
- NCT00450203
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇬🇧Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧Cumberland Infirmary, Carlisle, England, United Kingdom
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 189
- Registration Number
- NCT00432172
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇪🇸Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
🇪🇸Centro Oncológico Regional de Galicia, A Coruña, Spain
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 100
- Registration Number
- NCT00431795
- Locations
- 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2008-01-21
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 478
- Registration Number
- NCT00431080
- Locations
- 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 272
- Registration Number
- NCT00429871
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷401 Military Hospital of Athens, Athens, Greece
Breast Cancer Treated by Neoadjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Centre Jean Perrin
- Target Recruit Count
- 264
- Registration Number
- NCT00425516
- Locations
- 🇫🇷
Hospital center, Brive La Gaillarde, France
🇫🇷Centre Jean Perrin, Clermont Ferrand, France
🇫🇷Edouard Herriot University Hospital, Lyon, France
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 658
- Registration Number
- NCT00424606
- Locations
- 🇬🇷
University Hospital of Heraklion, Heraklion, Crete, Greece
🇬🇷University Hospital of Alexandroupolis Dept. of Medical Oncology, Alexandroupolis, Greece
🇬🇷"Laikon" General Hospital, Athens, Greece
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 273
- Registration Number
- NCT00336791
- Locations
- 🇪🇸
Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
🇲🇽Centro Medico Nacional de Occidente, Guadalajara, Mexico
Phase I Combination w/ Epirubicin
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 42
- Registration Number
- NCT00322374
- Locations
- 🇮🇹
Local Institution, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.